Scotiabank analyst Greg Harrison lowered the firm’s price target on Travere Therapeutics (TVTX) to $30 from $32 and keeps an ...

Greenberg Traurig, LLP's London office has been shortlisted in three categories, including Best Client Service, Corporate Team of the Year, and Real Estate Team of the Year, at The Lawyer Awards 2025.

LivePerson, Inc. is providing confirmatory notice, in compliance with the requirements of Nasdaq Listing Rule 5635(c)(4), of recent grants of equity-based incentive awards that LivePerson made under ...

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on April 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting ...

A post-hoc analysis of the DUPLEX trial shows significantly greater improvements in proteinuria-related outcomes vs irbesartan for tough-to-treat FSGS.

Scotiabank analyst Greg Harrison maintained a Buy rating on Travere Therapeutics (TVTX – Research Report) today and set a price target of ...

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

A group of biotech CEOs, investors, and patient advocates have urged Senate HELP Committee Chairman Bill Cassidy (R-LA) to ...

Adults recently diagnosed with immunoglobulin A nephropathy who were assigned sparsentan as first-line therapy experienced rapid and sustained reductions in proteinuria, according to ...

Canaccord analyst Edward Nash raised the firm’s price target on Travere Therapeutics (TVTX) to $47 from $45 and keeps a Buy rating on the ...

As the U.S. market experiences heightened volatility with major indices like the S&P 500 and Nasdaq Composite closing sharply lower amid tariff concerns, investors are closely monitoring economic ...

Travere Therapeutics (NASDAQ:TVTX – Get Free Report)‘s stock had its “overweight” rating reiterated by equities research analysts at Cantor Fitzgerald in a research report issued to clients and ...